Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis

Ann Rheum Dis. 2021 Jan;80(1):e9. doi: 10.1136/annrheumdis-2020-217634. Epub 2020 May 4.

Authors

Francesca Romana Spinelli¹, Fulvia Ceccarelli², Manuela Di Franco², Fabrizio Conti²

Affiliations

¹ Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Italy francescaromana.spinelli@uniroma1.it.
² Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari-Reumatologia, Sapienza University of Rome, Roma, Italy.

PMID: 32366521
DOI: 10.1136/annrheumdis-2020-217634

No abstract available

Keywords: arthritis, rheumatoid; autoimmune diseases; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

Antimalarials* / therapeutic use
COVID-19*
Humans
Hydroxychloroquine
Pandemics / prevention & control
SARS-CoV-2

Substances

Antimalarials
Hydroxychloroquine